117 related articles for article (PubMed ID: 31567386)
1. Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy.
Ma R; Huang XJ; Jia JS; Kong J; Qin YZ; Jiang H
Chin Med J (Engl); 2019 Oct; 132(20):2498-2500. PubMed ID: 31567386
[No Abstract] [Full Text] [Related]
2. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
Tang TC; Chang H; Chuang WY
Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
[TBL] [Abstract][Full Text] [Related]
3. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
Srinivas U; Barwad A; Pubbaraju SV
Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
[No Abstract] [Full Text] [Related]
4. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
5. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract][Full Text] [Related]
6. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
7. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
8. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
10. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
[No Abstract] [Full Text] [Related]
11. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
Hilal T; Fauble V; Ketterling RP; Kelemen K
Cancer Genet; 2018 Jan; 220():13-18. PubMed ID: 29310833
[TBL] [Abstract][Full Text] [Related]
12. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Kim DS; Lee S; Choi CW
Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
[No Abstract] [Full Text] [Related]
13. Pathological fracture due to lytic lesion caused by a myeloid neoplasm with FIP1L1-PDGFRA.
McGregor AK; Greystoke B; Wood K; Bedwell C; Oakes R
Br J Haematol; 2016 Sep; 174(5):660. PubMed ID: 27391191
[No Abstract] [Full Text] [Related]
14. Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder.
Lyall H; O'Connor S; Clark D
Br J Haematol; 2007 Aug; 138(4):405. PubMed ID: 17593250
[No Abstract] [Full Text] [Related]
15. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in the treatment of hematologic malignancies.
Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
[TBL] [Abstract][Full Text] [Related]
17. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
18. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
19. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
20. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
